Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 3351 to 3400 of 3761 results for treatment

  1. Cochlear implants for children and adults with severe to profound deafness (TA566)

    Evidence-based recommendations on cochlear implants for children and adults with severe to profound deafness.

  2. Lapatinib for breast cancer (first line use in advanced or metastatic hormone-sensitive breast cancer) [ID115]

    Discontinued Reference number: GID-TAG404

  3. Preventing suicide in community and custodial settings (NG105)

    This guideline covers ways to reduce suicide and help people bereaved or affected by suicides. It aims to:

  4. Colon cancer (adjuvant) - irinotecan [ID379]

    In development Reference number: GID-TAG380 Expected publication date: TBC

  5. Multiple sclerosis (primary-progressive) - fingolimod [ID62]

    Discontinued Reference number: GID-TAG221

  6. Endoaortic balloon occlusion for cardiac surgery (HTG168)

    Evidence-based recommendations on endoaortic balloon occlusion for cardiac surgery. This involves inserting a tube with a balloon attached into the aorta and filling it with saline to block blood flowing from the heart so that surgery can be done.

  7. Percutaneous laser atherectomy as an adjunct to balloon angioplasty (with or without stenting) for peripheral arterial disease (HTG294)

    Evidence-based recommendations on percutaneous laser atherectomy as an adjunct to balloon angioplasty (with or without stenting) for peripheral arterial disease. This involves using a baloon to widen the artery at the site of the blockage.

  8. Planning your technology appraisal submission to NICE

    Engage at the optimal time for your technology appraisal, to achieve NICE guidance at the same time as marketing authorisation.

  9. Atrial fibrillation - ximelagatran [ID376]

    Discontinued Reference number: GID-TAG377

  10. Smoking: reducing and preventing tobacco use (QS82)

    This quality standard covers reducing and preventing tobacco use in adults, young people and children. It includes interventions to discourage people from taking up smoking, tobacco control strategies and smokefree policies. It is particularly relevant to local authorities, schools and colleges, employers and NHS service providers. It describes high-quality care in priority areas for improvement.

  11. Bimekizumab for treating active non-radiographic axial spondyloarthritis [ID4010]

    Discontinued Reference number: GID-TA11151

  12. Visensia for early detection of deteriorating vital signs in adults in hospital (MIB36)

    NICE has developed a medtech innovation briefing (MIB) on Visensia for early detection of deteriorating vital signs in adults in hospital

  13. Allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus (HTG165)

    Evidence-based recommendations on allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus. This involves removing cells called islet cells, which are responsible for the production of insulin, from human donors.

  14. Juvenile idiopathic arthritis - adalimumab [ID385]

    Discontinued Reference number: GID-TAG400

  15. Breast cancer (metastatic) -trastuzumab (as monotherapy and in combination with a taxane) [ID345]

    Discontinued Reference number: GID-TAG417

  16. Venous thromboembolism (VTE) - ximelagatran [ID396]

    Discontinued Reference number: GID-TAG378

  17. Osteoarthritis - naproxcinod [ID417]

    Discontinued Reference number: GID-TAG426

  18. Epilepsy: seizure free in preceding 12 months (IND145)

    This indicator covers the percentage of patients aged 18 or over on drug treatment for epilepsy who have been seizure free for the last 12 months recorded in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM110

  19. Diabetes: advice for erectile dysfunction (IND106)

    This indicator covers the percentage of male patients with diabetes who have a record of erectile dysfunction with a record of advice and assessment of contributory factors and treatment options in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM52

  20. Tanezumab for treating pain caused by bone metastases [ID3784]

    Discontinued Reference number: GID-TA10922

  21. Dexcom G6 for real-time continuous glucose monitoring (MIB233)

    NICE has developed a medtech innovation briefing (MIB) on Dexcom G6 for real-time continuous glucose monitoring .

  22. Serial transverse enteroplasty procedure (STEP) for bowel lengthening in parenteral nutrition-dependent children (HTG149)

    Evidence-based recommendations on the serial transverse enteroplasty procedure (STEP) for bowel lengthening in parenteral nutrition-dependent children. This involves cutting and stapling the bowel in a zig-zag pattern to narrow and lengthen it.

  23. Hepatitis C (genotype 1, chronic) - faldaprevir [ID670]

    Discontinued Reference number: GID-TAG456

  24. Guide to the technology appraisal and highly specialised technologies appeal process (PMG41)

    This guide outlines the appeal process for the technology appraisal and highly specialised technologies guidance. It sets out the process that NICE follows for appeals and provides guidance for those who wish to make an appeal or who are considering doing so

  25. Multiple myeloma - bortezomib (consolidation therapy) [ID529]

    Discontinued Reference number: GID-TAG320

  26. Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768]

    In development Reference number: GID-TAG499 Expected publication date: TBC

  27. Vemurafenib for treating resected BRAF V600 mutation-positive melanoma [ID1250]

    Discontinued Reference number: GID-TA10213

  28. Rigosertib for previously treated high-risk myelodysplastic syndrome [ID805]

    Discontinued Reference number: GID-TA10709

  29. Venous thromboembolism (recurrent) - idraparinux sodium [ID395]

    Discontinued Reference number: GID-TAG384

  30. Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions (MIB89)

    NICE has developed a medtech innovation briefing (MIB) on Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions .

  31. Renal cell carcinoma - sunitinib [ID1076]

    Discontinued Reference number: GID-TA10166

  32. Optical coherence tomography to guide percutaneous coronary intervention (HTG332)

    Evidence-based recommendations on optical coherence tomography to guide percutaneous coronary intervention. This involves using near-infrared light to produce high-resolution images of blood vessel walls.

  33. Technology appraisal data: cancer appraisal recommendations

    Data on the cancer recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.

  34. Resource planner

    Our resource planner tool to help you plan for and implement NICE guidance.

  35. Plus Sutures for preventing surgical site infection (HTG586)

    Evidence-based recommendations on Plus Sutures for preventing surgical site infection.

  36. Etirinotecan pegol for treating breast cancer with brain metastases [ID881]

    Discontinued Reference number: GID-TA10066

  37. Masitinib for treating amyotrophic lateral sclerosis [ID967]

    Discontinued Reference number: GID-TA10157

  38. Peezy Midstream for urine collection (MT446)

    In development Reference number: GID-MT538 Expected publication date: TBC

  39. NICE HealthTech programme manual (PMG48)

    This guide describes the methods and processes that NICE follows when producing HealthTech guidance. For interventional procedures, this guide covers NICE processes. Methods for interventional procedures guidance are in the NICE's interventional procedures programme manual. The NICE HealthTech programme combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme

  40. Digital technologies for multidisciplinary weight management

    In development Reference number: GID-HTE10077 Expected publication date: TBC

  41. Laquinimod for treating relapsing-remitting multiple sclerosis [ID560]

    Discontinued Reference number: GID-TAG337

  42. Endobronchial ultrasound-guided transbronchial needle aspiration for mediastinal masses (HTG163)

    Evidence-based recommendations on endobronchial ultrasound-guided transbronchial needle aspiration for mediastinal masses. This involves inserting a thin tube through the mouth into the lungs to take samples for examination.

  43. Making decisions using NICE guidelines

    People have the right to be able to make informed decisions about their care. Our guidance should be taken into account when making decisions with them.

  44. Cost saving guidance

    and management (NG59) Savings come from changes to the pharmacological treatments for people with acute or chronic severe sciatica. Cash...

  45. Sole supplied titles

    Sole supplied titles are distinct journal and book collections that can be purchased from Lot 1 of our purchasing framework.

  46. Psoriasis - briakinumab (suspended) [ID65]

    Discontinued Reference number: GID-TAG412

  47. ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]

    In development Reference number: GID-TA10489 Expected publication date: TBC

  48. Hemosep for cell salvage (MIB103)

    NICE has developed a medtech innovation briefing (MIB) on Hemosep for cell salvage .

  49. Safeguarding adults in care homes (NG189)

    This guideline covers keeping adults in care homes safe from abuse and neglect. It includes potential indicators of abuse and neglect by individuals or organisations, and covers the safeguarding process from when a concern is first identified through to section 42 safeguarding enquiries. There are recommendations on policy, training, and care home culture, to improve care home staff awareness of safeguarding and ensure people can report concerns when needed.

  50. Galcanezumab for preventing cluster headache [ID1212]

    Discontinued Reference number: GID-TA10425